Taiho Oncology and Cullinan Therapeutics said their EGFR inhibitor zipalertinib cleared a Phase 3 registrational test in the front-line setting for a genetically defined lung cancer population. The companies framed the result as lining up a potential competitive challenge involving Rybrevant, while positioning the therapy as next-generation targeted treatment. The update follows an accelerating tempo in EGFR space, where registrational readouts increasingly determine label expansion and sequencing strategies. The headline result also affects how clinicians might consider oral targeted options earlier in treatment for molecularly defined patients. For Cullinan and Taiho, the Phase 3 milestone is the latest step toward regulatory submissions and market planning, with the trial outcome now setting the bar for safety and efficacy comparisons against existing EGFR standards.